Yunnan Baiyao Group Co., Ltd.

Core Business

Yunnan Baiyao Group Co., Ltd. stands as a singularly iconic Chinese pharmaceutical enterprise whose name is synonymous with one of China's most recognized and trusted over-the-counter pharmaceutical brands, built upon a proprietary herbal formulation that has remained a closely guarded state secret since its development over a century ago. In fiscal year 2025, the company achieved consolidated revenue of RMB 41.19 billion, while net profit attributable to shareholders reached a record RMB 5.15 billion, representing a robust year-on-year increase of 8.51 percent, with recurring net profit after deducting non-recurring items reaching an all-time high of RMB 4.87 billion, underscoring the fundamental operational strength of the core pharmaceutical business. The company's flagship aerosol spray product achieved a historic milestone by surpassing RMB 2.5 billion in annual sales revenue, representing a remarkable growth rate of 22 percent year-on-year, while the topical medicated patch product line exceeded RMB 1.2 billion in annual sales with growth of 26 percent, demonstrating powerful brand revitalization and market share expansion dynamics even for mature product categories. Yunnan Baiyao's modern manufacturing operations are anchored by its state-of-the-art intelligent manufacturing center located in Chenggong district of Kunming city, featuring fully automated liquid formulation production lines capable of producing 120 individual packaging units per minute, representing the cutting edge of pharmaceutical manufacturing automation and quality control technology implementation in China's traditional medicine industry. The company has also developed significant business operations in proprietary traditional Chinese medicine raw material cultivation and processing, leveraging Yunnan province's unparalleled biodiversity and ideal climatic conditions for medicinal plant cultivation, which serves as a critical competitive advantage in raw material quality assurance and supply chain security. In a landmark strategic decision during fiscal year 2025, Yunnan Baiyao formally and completely exited all secondary market securities investment activities, returning the company's entire strategic focus and capital allocation discipline exclusively to its core pharmaceutical and healthcare business operations, including promising research programs in nuclear medicine and radiopharmaceutical applications. The company currently employs approximately 9,277 personnel, representing a highly skilled workforce optimized for pharmaceutical research, precision manufacturing, quality assurance, and market expansion activities.

Global Presence

Yunnan Baiyao's international commercial presence, while still representing a relatively small proportion of total consolidated group revenue, has been systematically expanding through targeted market entry strategies that leverage the brand's unique heritage and the growing global consumer interest in traditional botanical medicine products with documented clinical efficacy. The company's hemostatic powder, aerosol spray, and topical patch products have secured regulatory registration and commercial distribution in multiple Southeast Asian markets including Vietnam, Thailand, Malaysia, Singapore, and Myanmar, where the Yunnan Baiyao brand benefits from shared cultural appreciation of traditional herbal medicine and established diaspora consumer communities familiar with the product's reputation. The company has also pursued regulatory product registrations in selected Middle Eastern and Eastern European markets, where traditional botanical medicine enjoys growing consumer acceptance and where regulatory frameworks are progressively evolving to accommodate scientifically validated herbal preparations. Yunnan Baiyao participates actively in international pharmaceutical exhibitions and trade forums including CPhI China, the World Traditional Medicine Conference, and various ASEAN healthcare industry events, using these platforms to educate international buyers, distributors, and regulatory officials about the clinical evidence base supporting its proprietary formulations. The company has established research collaboration partnerships with academic medical centers and pharmacology departments at universities in Australia, Japan, and the United States, focusing on scientific investigation of the molecular mechanisms underlying Yunnan Baiyao's documented hemostatic, anti-inflammatory, and wound-healing therapeutic effects. These collaborative research programs generate peer-reviewed scientific publications that progressively build the international clinical evidence base required for regulatory submissions in more stringently regulated developed-country pharmaceutical markets. The company's international business development team continues to evaluate market entry opportunities in additional geographic territories, particularly those with large ethnic Chinese diaspora populations or established traditions of botanical medicine usage. Cross-border e-commerce channels have also emerged as an increasingly important direct-to-consumer international distribution pathway, enabling overseas consumers to purchase authentic Yunnan Baiyao products directly while ensuring product traceability and authenticity verification throughout the supply chain.

Key Strengths

Yunnan Baiyao's most profound and enduring competitive advantage derives from its possession of one of China's exceedingly rare national-level protected pharmaceutical formulation secrets, a legal and regulatory status that creates an essentially insurmountable barrier to competitive imitation and generational substitution that no rival pharmaceutical company can legally breach or circumvent. This unique intellectual property protection mechanism, combined with over a century of accumulated consumer trust and clinical usage data, establishes Yunnan Baiyao as genuinely irreplaceable within the Chinese pharmaceutical landscape, conferring extraordinary pricing power, sustained physician recommendation rates, and deeply ingrained consumer brand loyalty that spans multiple generations. The company's manufacturing operations strategy has been transformed through significant capital investment in intelligent automation and digital quality control systems, with the Chenggong intelligent manufacturing center representing a showcase facility that achieves pharmaceutical production precision, throughput efficiency, and quality consistency levels comparable to the most advanced pharmaceutical manufacturing facilities globally. This manufacturing excellence translates directly into superior gross profit margins, reduced quality deviation incidents, and enhanced regulatory compliance capabilities that support both domestic market leadership and international market expansion ambitions. The company's strategic pivot away from financial market securities investment and back toward core pharmaceutical research and development represents a critically important capital allocation discipline improvement that should progressively reduce earnings volatility and increase management focus on value-creating pharmaceutical innovation. Yunnan Baiyao's proprietary access to the unique botanical resources and biodiversity of Yunnan province, one of the most biologically diverse regions on Earth, provides raw material quality advantages and supply chain security that pharmaceutical companies in other geographic regions cannot replicate, particularly for the specialized herbal ingredients required by its protected formulations. The company's emerging nuclear medicine and radiopharmaceutical research programs represent a strategically prescient diversification initiative into a high-barrier, high-growth therapeutic area where Yunnan Baiyao's brand credibility in traditional medicine could be leveraged alongside modern radiopharmaceutical technology to create truly novel combination therapeutic approaches. The company's strong balance sheet position, conservative debt profile, and robust free cash flow generation from mature flagship products provide ample financial capacity to fund multi-year research and development programs, pursue strategic acquisitions, and maintain competitive dividend distributions to shareholders without compromising strategic investment requirements. The Yunnan Baiyao brand's cultural resonance throughout Chinese-speaking communities worldwide provides a natural international expansion pathway that most pharmaceutical companies lack, enabling market entry strategies that leverage existing brand awareness and trust rather than requiring expensive de novo brand building campaigns in unfamiliar foreign markets. VerityRank Score of 89/100

Yunnan Baiyao Group Co., Ltd. is an iconic Chinese pharmaceutical enterprise centered around one of China's most recognized and trusted over-the-counter medicine brands, built upon a proprietary herbal formulation that holds national-level protected secret status. The company achieved revenue of RMB 41.19 billion in 2025 with net profit reaching a record RMB 5.15 billion, driven by its flagship aerosol spray product surpassing RMB 2.5 billion in annual sales and medicated patches exceeding RMB 1.2 billion. Manufacturing operations are anchored by a state-of-the-art intelligent manufacturing center in Kunming featuring fully automated production lines with a throughput of 120 units per minute. In 2025, the company made the landmark strategic decision to fully exit secondary market securities investment, refocusing all capital and management attention on its core pharmaceutical operations and emerging nuclear medicine research programs. The company employs approximately 9,277 personnel and leverages Yunnan province's unparalleled biodiversity for proprietary raw material cultivation and processing.

Hemostatic pharmaceutical products, TCM preparations, oral care, personal care, functional health beverages, medical devices